⚠ Evidence warning: Clinical trials or other evidence do not support the proposed ways nattokinase lowers blood pressure in people (angiotensin-converting enzyme inhibition, better small-vessel blood flow, blood-vessel lining repair) or the combined reductions described for it alongside lifestyle change. This page keeps it as a report of what people, websites or other media say.
Nattokinase for Blood Pressure
Nattokinase has been studied for blood pressure reduction in two well-conducted randomized controlled trials: the Kim 2008 trial in 86 mildly hypertensive Korean adults (2,000 fibrinolytic units (FU)/day for 8 weeks, average reductions of 5.6 mmHg systolic and 2.8 mmHg diastolic versus placebo) and the Jensen 2016 multicenter North American trial in 79 adults with elevated blood pressure (a significant 3 mmHg fall in diastolic pressure versus placebo; the fall in systolic pressure did not differ significantly from placebo; and a downward trend in von Willebrand factor, a marker of blood-vessel-lining (endothelial) dysfunction and cardiovascular risk, in women only). A 2023 pooled analysis of 6 trials estimated an average fall of about 3.5/2.3 mmHg versus placebo. Two mechanisms are proposed: in laboratory tests, nattokinase-derived peptides have angiotensin-converting enzyme (ACE) inhibitor-like activity (the same enzyme inhibition exploited by pharmaceutical drugs like lisinopril and enalapril), and fibrinolysis-mediated improvement of microcirculation is thought to reduce peripheral vascular resistance independently. The honest summary: a modest effect, described as adjunctive support for prehypertension and stage 1 hypertension alongside lifestyle change, magnesium, potassium-rich diet, and weight management. The trials enrolled people with untreated, mildly raised blood pressure; nattokinase has not been tested as a substitute for prescribed antihypertensives in moderate-to-severe hypertension. In a human study it lowered the clotting factors fibrinogen, factor VII and factor VIII, an effect that adds to that of anticoagulant and antiplatelet drugs (blood thinners).
Table of Contents
- The Kim 2008 Randomized Controlled Trial — The Pivotal Hypertension Trial
- The Jensen 2016 North American Multicenter Trial
- A 2023 Pooled Analysis of the Trials
- Mechanism 1: ACE-Inhibitor-Like Activity in Laboratory Tests
- Mechanism 2: Microcirculation Improvement via Fibrinolysis
- Possible Mechanism 3: A von Willebrand Factor Trend in Women
- Magnitude of Effect — What 5/3 mmHg Actually Means
- Prehypertension and Stage 1 Hypertension — Where Its Use Is Discussed
- Combination with Magnesium, Potassium, and Lifestyle Change
- When Nattokinase Is NOT Appropriate for Blood Pressure
- Dosing and Time-to-Effect for Blood Pressure
- Cautions and Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
The Kim 2008 Randomized Controlled Trial — The Pivotal Hypertension Trial
The Kim 2008 trial published in Hypertension Research is the single most-cited human study supporting nattokinase for blood pressure reduction. Design and results:
- Population: 86 Korean adults aged 20–80 with pre-hypertension or stage 1 hypertension (untreated systolic blood pressure 130–159 mmHg) recruited from a university hospital outpatient clinic; 73 completed the trial.
- Design: Randomized, double-blind, placebo-controlled, parallel-group design. Stratified randomization to ensure balanced baseline blood pressure between arms.
- Intervention: 2,000 FU/day nattokinase (one capsule of a standardized nattokinase extract) vs. matching placebo capsule. Daily dose, single intake.
- Duration: 8 weeks of intervention.
- Endpoints: Office systolic and diastolic blood pressure measured at baseline, 4 weeks, and 8 weeks by a blinded study clinician.
Results at 8 weeks:
- Systolic blood pressure (BP): Compared with the placebo group, the net change was −5.55 mmHg (95% confidence interval (CI) −10.5 to −0.57); the between-group difference was statistically significant (P < 0.05).
- Diastolic blood pressure: Compared with the placebo group, the net change was −2.84 mmHg (95% confidence interval −5.33 to −0.33); also statistically significant (P < 0.05).
- Renin: Plasma renin activity fell by 1.17 ng/mL/h in the nattokinase group compared with the control group (P < 0.05). Renin is the first step of the same hormone chain (the renin-angiotensin system) that angiotensin-converting enzyme belongs to; this was the one mechanism the trial measured.
- Safety: No serious adverse events. No clinically significant changes in coagulation parameters at this dose. Tolerability was excellent.
The Kim trial established the 2,000 FU/day standard dose for blood pressure use, and the 8-week onset-to-significant-effect timeframe. The magnitude of reduction was modest but consistent and clinically meaningful in the mildly-hypertensive population studied.
The Jensen 2016 North American Multicenter Trial
The Jensen 2016 trial published in Integrated Blood Pressure Control was the first major confirmatory trial in a North American population, addressing one of the principal questions left open by the Kim study (whether the result would replicate outside an East Asian population that consumes substantial dietary natto and soy and may have different baseline cardiovascular risk profiles).
Design and results:
- Population: 79 adults from multiple North American clinical sites with elevated blood pressure (systolic ≥130 mmHg or diastolic ≥90 mmHg, confirmed on three separate screening days), not on blood pressure medication; 74 completed the study.
- Design: Randomized, double-blind, placebo-controlled, multicenter.
- Intervention: 100 mg/day of a standardized nattokinase extract (at least 2,000 FU per daily dose) vs. placebo for 8 weeks.
- Endpoints: Office blood pressure, plus von Willebrand factor (vWF) as a marker of endothelial activation, plasma renin activity and platelet factor-4, plus standard safety labs.
Results:
- Systolic blood pressure in the nattokinase group fell on average from 144 to 140 mmHg, only a statistical trend (P < 0.1); the decrease was not significantly different from the placebo group.
- Diastolic blood pressure fell from 87 to 84 mmHg in the nattokinase group, a significant difference from the placebo group, where it stayed at 87 mmHg (P < 0.05).
- Von Willebrand factor showed a downward trend in women only (P < 0.1), which did not reach statistical significance. vWF is a marker of endothelial dysfunction; the authors read the difference between the sexes as a sign of sex-specific mechanisms.
- Sex differences: the reduction in systolic blood pressure was seen in both sexes but was more robust in men, and in men taking nattokinase diastolic pressure fell from 86 to 81 mmHg (P < 0.006). The only finding specific to women was the von Willebrand factor trend.
- No serious adverse events; tolerability comparable to placebo.
The Jensen trial partly confirmed the blood pressure-lowering signal in a non-Asian population with relatively low background dietary natto/soy intake: diastolic pressure fell significantly compared with placebo, while the systolic fall did not differ from placebo. Its von Willebrand factor result, a trend in women only, hints at a mechanism beyond simple ACE-inhibitor-like activity but does not establish one.
A 2023 Pooled Analysis of the Trials
A 2023 systematic review and meta-analysis in Reviews in Cardiovascular Medicine (Li and colleagues) pooled 6 randomized controlled trials with 546 participants. Compared with placebo, nattokinase lowered systolic blood pressure by an average of 3.45 mmHg (95% confidence interval −4.37 to −2.18) and diastolic blood pressure by 2.32 mmHg (−2.72 to −1.92).
The same analysis found some changes in the other direction. Total cholesterol was slightly higher in the nattokinase groups than in the comparison groups, at both lower and higher total doses; at lower total doses, high-density lipoprotein (HDL, "good") cholesterol was a little lower and low-density lipoprotein (LDL) cholesterol a little higher; and blood glucose rose slightly. Triglycerides did not change, and no notable adverse events from nattokinase were reported in any of the trials. The authors concluded that the results support nattokinase as an adjunctive therapy for hypertension, and that more work is needed to learn whether its effects depend on the dose.
Mechanism 1: ACE-Inhibitor-Like Activity in Laboratory Tests
Angiotensin-converting enzyme is the zinc-metalloprotease that converts angiotensin I to angiotensin II, the principal effector of the renin-angiotensin-aldosterone system (RAAS) and one of the most potent endogenous vasoconstrictors. Angiotensin-converting enzyme inhibitors (lisinopril, enalapril, ramipril, perindopril) are first-line antihypertensive drugs precisely because blocking this enzyme reduces angiotensin II production, lowers vascular tone, reduces aldosterone-mediated sodium retention, and reduces cardiac afterload.
In laboratory (test-tube) tests, nattokinase inhibited angiotensin-converting enzyme (Murakami 2012); the inhibition grew much stronger when heat broke the enzyme apart into small peptides (such as LY and FY), and the authors traced it to those peptides rather than to the enzyme's own protein-cutting action. Beyond this, the fermentation process that produces nattokinase also produces a family of short bioactive peptides with documented ACE-inhibitory activity. These peptides are released by bacterial proteolysis of soy protein during fermentation. The same general phenomenon is well-documented for other fermented foods — the Yamamoto 1994 paper documenting ACE-inhibitory peptides from lactobacillus-fermented milk is a classic example, and there is now substantial literature on antihypertensive peptides from various fermented dairy and soy products.
The ACE inhibition produced by natto-derived peptides is several orders of magnitude weaker than pharmaceutical angiotensin-converting enzyme inhibitors on a molar basis, but the concentrations achieved in the gastrointestinal tract and (to a lesser extent) in plasma after natto consumption are correspondingly higher. Whether this adds up to a meaningful ACE inhibition in people has not been measured directly; the Kim trial measured renin, an earlier step in the same chain, and found it lower with nattokinase.
This mechanism is partially distinct from the fibrinolytic mechanism of nattokinase itself. Some of the ACE-inhibitory effect comes from peptides cut from the nattokinase protein itself, and some is from co-formulated soy-fermentation peptides that may be present in greater or lesser amounts depending on how the supplement was manufactured. Pure nattokinase preparations have less of this effect than less-purified natto-extract products.
Mechanism 2: Microcirculation Improvement via Fibrinolysis
The second proposed mechanism by which nattokinase may lower blood pressure is fundamentally different from the ACE-inhibitor mechanism: it is thought to work through reduction of peripheral vascular resistance via improved blood rheology rather than through direct effects on the vascular wall.
The chain of logic is:
- Nattokinase reduces plasma fibrinogen (~7–10% in the Hsia trial)
- Lower fibrinogen reduces whole-blood viscosity (Pais 2006)
- Lower fibrinogen also reduces red-cell aggregation at low shear rates, improving microcirculatory perfusion (Pais 2006)
- Improved microcirculation at the level of the resistance arterioles and capillaries reduces total peripheral vascular resistance
- By the equation blood pressure = cardiac output × total peripheral resistance, reduced total peripheral resistance translates to lower blood pressure at constant cardiac output
This mechanism is a slower-onset, lower-magnitude contributor to blood pressure reduction than the ACE-inhibitor-like activity, but it operates through a fundamentally distinct pathway and the two effects are likely additive rather than redundant. The combined ACE-inhibitor + microcirculation-improvement mechanism is proposed to explain why the magnitude of blood pressure reduction in the Kim trial (~5/3 mmHg) is greater than would be predicted from the ACE-inhibitory activity alone of natto-derived peptides.
For more on the cardiovascular significance of reduced fibrinogen and improved blood rheology, see the cardiovascular and fibrinolysis deep-dive.
Possible Mechanism 3: A von Willebrand Factor Trend in Women
The Jensen 2016 trial added a finding that was not the primary endpoint but is mechanistically interesting: von Willebrand factor (vWF) decreased among the women taking nattokinase, only as a trend (P < 0.1) that did not reach statistical significance. vWF is a large multimeric glycoprotein produced by endothelial cells and stored in Weibel-Palade bodies; it is released into circulation in response to endothelial activation, inflammation, and shear stress, and serves as a marker of endothelial dysfunction.
Elevated vWF is independently associated with cardiovascular disease risk, particularly thrombotic events. Lowering vWF is not in itself an antihypertensive mechanism, but a lower vWF would reflect improvement in endothelial health, which is a fundamental driver of long-term blood pressure regulation through nitric oxide production, endothelin balance, and prostacyclin synthesis.
The proposed mechanism for a vWF reduction is reduced endothelial inflammation and reduced oxidative stress, secondary to reduced fibrinogen, reduced low-density lipoprotein (LDL) oxidation, and improved microcirculatory perfusion of the endothelium itself. The endothelium is metabolically active tissue and is sensitive to its own perfusion; chronically under-perfused endothelium expresses more vWF, more endothelin, less nitric oxide, all of which raise blood pressure. Whether sustained nattokinase use reverses this cascade has not been tested.
Magnitude of Effect — What 5/3 mmHg Actually Means
A 5/3 mmHg reduction sounds modest, and at the individual level it often is. But cardiovascular epidemiology has consistently shown that population-level reductions of even 2–3 mmHg in systolic blood pressure translate to clinically meaningful reductions in cardiovascular events. The Prospective Studies Collaboration meta-analysis (61 prospective observational studies, over a million participants) showed that each 2 mmHg reduction in usual systolic blood pressure is associated with approximately 7% lower ischemic heart disease mortality and 10% lower stroke mortality. The 5/3 mmHg reduction seen in the Kim trial would therefore correspond to a roughly 15–20% reduction in projected cardiovascular event risk if sustained.
The key qualifier is "if sustained." The 8-week trial duration of both Kim and Jensen is too short to demonstrate event-rate reductions directly, and no long-term outcome trial of nattokinase has been performed. The benefit is inferred from the established relationship between blood pressure reduction and cardiovascular events that has been documented for pharmaceutical antihypertensives. Whether nattokinase achieves the same cardiovascular benefit per mmHg of blood pressure reduction as an angiotensin-converting enzyme inhibitor or thiazide diuretic is not established; it is plausible based on shared mechanism but is an inference.
Other things are not known either. In the Jensen trial the systolic fall did not differ from placebo. There are only a few short (8-week) trials. And the 2023 pooled estimate (−3.45/−2.32 mmHg) is smaller than the 5/3 mmHg used for the 15–20% projection above, so a projection based on it would be smaller too.
The honest framing for patients: in the Kim trial nattokinase lowered systolic blood pressure by about 5.5 mmHg compared with placebo, and the 2023 pooled analysis estimated about 3.5 mmHg; a 5 mmHg fall is similar to what would be expected from moderate weight loss (~5 kg) or the DASH (Dietary Approaches to Stop Hypertension) diet, and approximately half what would be expected from a low-dose pharmaceutical antihypertensive. It is discussed as one part of a multi-component blood pressure management strategy; the trials did not test it as a standalone substitute for prescription medication in moderate-to-severe hypertension.
Prehypertension and Stage 1 Hypertension — Where Its Use Is Discussed
The clinical situation in which proponents see the strongest case for nattokinase is the prehypertension (120–129 / <80 mmHg) and stage 1 hypertension (130–139 / 80–89 mmHg) range, where:
- Pharmaceutical antihypertensive therapy is often not yet indicated by current guidelines (which favor lifestyle change as first-line in this range, with medication reserved for higher blood pressure or for patients with multiple cardiovascular risk factors)
- A 5/3 mmHg reduction can shift the patient from "borderline elevated" to "normal," with attendant reduction in long-term cardiovascular risk
- The patient is motivated to do something but not yet at the stage where the benefit/risk ratio favors starting daily prescription medication
- The relatively favorable safety profile of nattokinase (in patients NOT on anticoagulants or antiplatelet drugs) makes it a low-risk addition to lifestyle change
The typical patient profile in which nattokinase is discussed as an addition: a 45–65 year old with average blood pressure in the 130–140 / 82–88 range, no diabetes, normal kidney function, normal coagulation, not on any antithrombotic medication, who is already implementing weight loss, exercise, and dietary sodium reduction and is looking for an additional modality. In this patient nattokinase 2,000 FU/day for 8–12 weeks may produce a clinically meaningful additional 5 mmHg reduction beyond what lifestyle alone achieves.
For more on hypertension itself and its non-pharmaceutical management, see our Hypertension page.
Combination with Magnesium, Potassium, and Lifestyle Change
Proponents describe nattokinase as most effective when combined with the other established non-pharmaceutical blood pressure interventions. The combinations are mechanistically additive because they work through different pathways:
- Nattokinase — proposed ACE-inhibitor-like activity + microcirculation improvement + possible vWF reduction; expected reduction ~5/3 mmHg (Kim 2008)
- Magnesium glycinate or citrate (300–400 mg/day) — vascular smooth-muscle relaxation, improved nitric oxide bioavailability; expected reduction ~2–4 mmHg systolic in deficient subjects. See Magnesium page.
- Potassium-rich diet (3,500–4,700 mg/day from food) — reduced sodium-driven volume expansion via natriuretic effect at the distal nephron; expected reduction ~3–5 mmHg systolic. See Potassium-rich foods.
- DASH or Mediterranean diet pattern — combined effect of reduced sodium, increased potassium, increased fiber, reduced refined carbohydrate; expected reduction ~5–11 mmHg systolic. See Anti-Inflammatory Diet.
- Aerobic exercise 150+ minutes per week — improved endothelial function, reduced sympathetic tone; expected reduction ~4–9 mmHg systolic.
- Weight loss in overweight patients — approximately 1 mmHg per 1 kg lost up to 5–10 kg loss.
- Reduced alcohol intake (no more than 1 drink/day women, 2 drinks/day men) — expected reduction ~2–4 mmHg systolic in heavier drinkers.
The combined effect of nattokinase + magnesium + potassium-rich diet + DASH pattern + exercise can easily exceed 15–20 mmHg systolic reduction in a motivated patient, which is comparable to a single-agent pharmaceutical antihypertensive. This combination strategy is the practical foundation of non-pharmaceutical hypertension management for prehypertension and stage 1 hypertension.
When Nattokinase Is NOT Appropriate for Blood Pressure
- Stage 2 hypertension (≥140/90 mmHg). Pharmaceutical antihypertensive therapy is indicated at this level; nattokinase has not been tested as a substitute. When it is taken alongside prescribed drugs, its lowering of the clotting factors fibrinogen, factor VII and factor VIII (Hsia 2009) adds a bleeding consideration.
- Hypertensive urgency or emergency (≥180/110 mmHg). Hospitals treat these readings as urgent and use immediate drug treatment; nattokinase has no studied role.
- Patients on warfarin, apixaban, rivaroxaban, edoxaban, dabigatran, aspirin, clopidogrel, or ticagrelor. In a human study, nattokinase at 4,000 FU/day for 2 months lowered the clotting factors fibrinogen (by 7–10%), factor VII (by 7–14%) and factor VIII (by 17–19%) (Hsia 2009); these drops add to the effect of these blood thinners and raise bleeding risk.
- Patients with active bleeding disorders, hemophilia, von Willebrand disease, thrombocytopenia, or recent hemorrhagic stroke.
- Pregnant or lactating women. Insufficient safety data.
- Patients within 7 days of any planned surgery or invasive procedure.
- Hypertension secondary to a treatable cause — renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing syndrome, obstructive sleep apnea. These are treated by addressing the underlying cause; nattokinase has not been studied as a substitute therapy.
- Patients with severe soy allergy who cannot find a verified soy-free preparation.
Dosing and Time-to-Effect for Blood Pressure
- Standard dose: 2,000 FU once daily — the dose used in both the Kim 2008 and Jensen 2016 positive trials.
- Higher-dose option: 2,000 FU twice daily (4,000 FU total) for patients who do not respond at 2,000 FU after 8 weeks. The marginal benefit of higher doses for blood pressure alone is not well-established; most of the published positive evidence is at 2,000 FU.
- Time-of-day: evening dosing is theoretically rational because endogenous fibrinolytic activity is lowest in the early morning, and many trials used evening dosing. Whether this matters for the blood pressure effect specifically (as opposed to the cardiovascular event prevention effect) is not established.
- With or without food: enteric-coated capsules can be taken either way; most patients take them with the evening meal.
- Time to measurable blood pressure effect: 4–8 weeks of daily dosing. The trials reported effects after weeks of daily use, not same-day or first-week effects.
- Trial duration before deciding: 8–12 weeks. Practitioners describe someone with no measurable effect at 12 weeks at 2,000–4,000 FU/day as likely not a responder.
- Monitoring: home blood pressure cuff readings 3–5 times per week, recorded with date/time, give an objective trend. Office blood pressure alone is too noisy to detect a 5 mmHg effect reliably.
Cautions and Drug Interactions
- Anticoagulants (warfarin, apixaban, rivaroxaban, edoxaban, dabigatran) — in a human study, nattokinase at 4,000 FU/day for 2 months lowered the clotting factors fibrinogen (by 7–10%), factor VII (by 7–14%) and factor VIII (by 17–19%) (Hsia 2009), which adds to the effect of these blood thinners. The interaction can be clinically significant.
- Antiplatelets (aspirin, clopidogrel, ticagrelor, prasugrel) — the same added effect on clotting applies.
- Pharmaceutical angiotensin-converting enzyme inhibitors (lisinopril, enalapril, ramipril, perindopril) — the combined ACE inhibition could theoretically produce additive blood pressure reduction beyond what was intended; the concern is excessive blood pressure reduction or symptomatic low blood pressure (hypotension). In practice this combination is described as generally well-tolerated; home blood pressure readings show whether pressure falls too far.
- Pharmaceutical angiotensin receptor blockers (losartan, valsartan, irbesartan, candesartan) — theoretical additive effect on blood pressure.
- Beta blockers, calcium channel blockers, diuretics — the combined effect is described as generally well-tolerated; home blood pressure readings show the combined effect.
- Active bleeding disorders, hemophilia, von Willebrand disease, thrombocytopenia. Contraindicated.
- Recent or planned surgery — because of its effect on clotting factors, nattokinase is commonly stopped at least 7 days before a procedure.
- Pregnancy and lactation. Insufficient safety data.
- Soy allergy. Nattokinase comes from fermented soy (natto); some preparations are verified soy-free.
- Side effects. Generally mild — nausea, gastrointestinal discomfort, occasional bruising, infrequent menstrual flow increase.
For more on the broader context of cardiovascular risk reduction, see Hypertension, Atherosclerosis, and Lipid Panel.
Key Research Papers
- Kim JY et al. (2008). Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research 31(8):1583-1588. — PubMed PMID: 18971533
- Jensen GS et al. (2016). Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integr Blood Press Control. — PubMed PMID: 27785095
- Murakami K, Yamanaka N, Ohnishi K, Fukayama M, Yoshino M (2012). Inhibition of angiotensin I converting enzyme by subtilisin NAT (nattokinase) in natto, a Japanese traditional fermented food. Food Funct. — PubMed PMID: 22453301
- Yamamoto N, Akino A, Takano T (1994). Antihypertensive effect of the peptides derived from casein by an extracellular proteinase from Lactobacillus helveticus CP790. J Dairy Sci. — PubMed PMID: 8201050
- Hsia CH et al. (2009). Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. Nutr Res. — PubMed PMID: 19358933
- Lewington S et al. (Prospective Studies Collaboration, 2002). Age-specific relevance of usual blood pressure to vascular mortality: meta-analysis of individual data for one million adults. Lancet. — PubMed PMID: 12493255
- Sacks FM et al. (DASH-Sodium Collaborative Research Group, 2001). Effects on blood pressure of reduced dietary sodium and the DASH dietary pattern. NEJM. — PubMed PMID: 11136953
- Chen H et al. (2018). Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases. Biomark Insights. — PubMed PMID: 30013308
- Li X, Long J, Gao Q, et al. (2023). Nattokinase supplementation and cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. Rev Cardiovasc Med. — PubMed PMID: 39076715
PubMed Topic Searches
Connections
- All Food
- Nattokinase Overview
- Nattokinase Benefits Hub
- Cardiovascular & Fibrinolysis
- Stroke Prevention
- Vitamin K2 (Menaquinone-7) Connection
- Hypertension
- Atherosclerosis
- Magnesium
- Potassium-Rich Foods
- Anti-Inflammatory Diet
- Natto (Food)
- Vitamin K
- Lipid Panel
- Coagulation Panel
- Omega-3 Fatty Acids
- Aspirin
- History